Navigation Links
Elekta VMAT Radiation Therapy Rapidly Gaining Users Worldwide as Technique Evolves
Date:2/12/2010

ATLANTA, Feb. 12 /PRNewswire/ -- Entering its third year of commercial availability, Elekta VMAT has garnered more than 200 orders, with many customers using the arc-based technique clinically since 2008. These clinical Elekta VMAT users have employed the method to treat hundreds of patients worldwide. With Elekta VMAT, single or multiple radiation beams sweep in uninterrupted arc(s) around the patient, reducing treatment times from the eight to 12 minutes required for standard radiation therapy to as few as two minutes.

"As a pioneer in arc-based radiation treatment, we are gratified to see the clinical and practical benefits of Elekta VMAT afforded to many hundreds of patients around the world," says Dee Mathieson, Senior Vice President, Oncology Business Line Management. "The current integration of the technique with an electronic medical record [EMR] system and introduction of an improved VMAT planning package on the horizon make Elekta VMAT a comprehensive treatment solution and the definitive arc-based technique on the market."

The 2009 meeting of the American Society for Radiation Oncology (ASTRO) featured numerous posters and presentations on Elekta VMAT studies. Summaries of selected studies:

  • Casa di Cura S. Chiara, Firenze, Italy: VMAT v. IMRT plan comparisons for prostate cancer. Result: Retrospective VMAT plans would provide shorter treatment times and lower radiation dose (fewer MU's).

  • University Medical Center Mannheim, Germany: IMRT v. VMAT in treatment of spinal metastases. Result: IMRT is superior to 3D conformal in target coverage, but had treatment times averaging 10 minutes. VMAT also provided an excellent dose distribution, but recorded treatment times of less than four minutes and lower dose (fewer MU's) compared to IMRT.

  • William Beaumont Hospital, Royal Oak, Michigan: VMAT for stereotactic body radiation therapy (SBRT) of lung and spine. Results: In two lung cases, VMAT reduced dose enough to enable SBRT. In three spine cases, radiation dose was reduced versus IMRT. Treatment times were decreased by up to 13 minutes or 59 percent.

At the University of Tokyo, clinicians led by Keiichi Nakagawa, M.D., radiation oncologist and professor in the department of radiology, have treated more than 60 prostate cancer patients with Elekta VMAT. The entire treatment takes just 10 minutes, encompassing patient room entry, imaging of the patient on the table to adjust treatment positioning, 100 seconds of VMAT beam-on-time and patient room exit.

Clinicians at University Medical Center Mannheim have been evaluating Elekta VMAT for a year, utilizing the technique for 15 patients with prostate or paraspinal tumors. This work confirmed for Mannheim doctors the ability of the Elekta treatment and control systems to deliver the radiation arcs rapidly and as specified in plans.

Patients with tumors in regions that are affected by motion, such as those in the lungs and prostate could benefit substantially from Elekta VMAT's speed, according to Frank Lohr, M.D., vice chair, department of radiation oncology at Mannheim. It also is beneficial for patients whose pain makes prolonged treatment sessions undesirable.

"For patients with bone metastases, for example, it will be a lot easier for them to tolerate a one to two minute Elekta VMAT treatment compared to the current five to seven minute treatment per session," he notes.

In the design of Elekta VMAT, Elekta has integrated the latest version of its digital control system, which facilitates clinical use of VMAT while emphasizing optimal patient safety.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.


Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.

SOURCE Elekta

RELATED LINKS
http://www.elekta.com

'/>"/>

SOURCE Elekta
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines
2. Elekta Launches New Web Site for Global Health Care Community
3. University of Virginia Acquires New Elekta Technology to Expand Patient Groups That Could Benefit From Gamma Knife Surgery
4. Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors
5. Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting
6. Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center
7. National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta
8. Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution
9. CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
10. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
11. Elektas New Line of Stereotactic Treatment Solutions is Redefining Excellence in Stereotaxy, a Case at a Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Edwards Lifesciences ... patient-focused innovations for structural heart disease and critical care ... accelerated share repurchase (ASR) agreement with Morgan Stanley & ... stock.  This repurchase is part of the Company,s previously ... the Company,s common stock.  --> ...
(Date:2/4/2016)... Feb. 4, 2016 Worldwide Radiology Oncology ... growth as next generation systems provide a way ... for cancer surgery. New systems pinpoint the delivery ... has been such a problem previously, limiting the ... robots take cancer surgery far beyond what has ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  SciClone ... today announced it has entered into a settlement ... Commission (SEC) fully resolving the SEC,s investigation into ... (FCPA).  Under the terms of the settlement agreement, ... $12.8 million, including disgorgement, pre-judgment interest and a ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth ... country gathered at the La Valencia Hotel in San Diego, California to discuss ... named the year’s most outstanding franchise, walking away with the coveted David Wright ...
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
Breaking Medicine News(10 mins):